

# Tim A Kanters

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7242971/publications.pdf>

Version: 2024-02-01

30  
papers

557  
citations

623574

14  
h-index

677027

22  
g-index

30  
all docs

30  
docs citations

30  
times ranked

1003  
citing authors

#	ARTICLE	IF	CITATIONS
1	Productivity of Working at Home and Time Allocation Between Paid Work, Unpaid Work and Leisure Activities During a Pandemic. <i>Pharmacoeconomics</i> , 2022, 40, 77-90.	1.7	13
2	Cost Effectiveness of Splenic Artery Embolization versus Splenectomy after Trauma in the Netherlands. <i>Journal of Vascular and Interventional Radiology</i> , 2022, 33, 392-398.e4.	0.2	3
3	In Absence of Absenteeism: Some Thoughts on Productivity Costs in Economic Evaluations in a Post-corona Era. <i>Pharmacoeconomics</i> , 2022, 40, 7-11.	1.7	6
4	Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision. <i>Pharmacoeconomics</i> , 2021, 39, 383-397.	1.7	11
5	Burden of Providing Informal Care for Patients with Atrial Fibrillation. <i>Value in Health</i> , 2021, 24, 236-243.	0.1	9
6	Good Days and Bad Days: Measuring Health-Related Quality of Life in People With Epilepsy. <i>Value in Health</i> , 2021, 24, 1470-1475.	0.1	3
7	Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab. <i>Breast</i> , 2020, 52, 71-77.	0.9	11
8	Evaluating the Effectiveness and Cost-Effectiveness of Seizure Dogs in Persons With Medically Refractory Epilepsy in the Netherlands: Study Protocol for a Stepped Wedge Randomized Controlled Trial (EPISODE). <i>Frontiers in Neurology</i> , 2020, 11, 3.	1.1	6
9	Assessing Costs Using the Treatment Inventory Cost in Psychiatric Patients (TIC-P), TIC-P Mini and TIC-P Midi. <i>Journal of Mental Health Policy and Economics</i> , 2019, 22, 15-24.	0.6	1
10	Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria. <i>British Journal of Dermatology</i> , 2018, 179, 702-708.	1.4	19
11	International differences in patient access to ultra-orphan drugs. <i>Health Policy and Technology</i> , 2018, 7, 57-64.	1.3	7
12	Decreased quality of life and societal impact of cryopyrin-associated periodic syndrome treated with canakinumab: a questionnaire based cohort study. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 59.	1.2	11
13	A cost of illness study of hypoglycaemic events in insulin-treated diabetes in the Netherlands. <i>BMJ Open</i> , 2018, 8, e019864.	0.8	18
14	Care-related Quality of Life of informal caregivers of the elderly after a hip fracture. <i>Journal of Patient-Reported Outcomes</i> , 2018, 2, 23.	0.9	16
15	Potential cost savings owing to the route of administration of oncology drugs. <i>Anti-Cancer Drugs</i> , 2018, 29, 791-801.	0.7	23
16	Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel. <i>Frontiers in Pharmacology</i> , 2017, 8, 322.	1.6	21
17	Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 179.	1.2	15
18	Update of the Dutch manual for costing studies in health care. <i>PLoS ONE</i> , 2017, 12, e0187477.	1.1	151

#	ARTICLE	IF	CITATIONS
19	Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up. <i>Journal of Inherited Metabolic Disease</i> , 2016, 39, 253-260.	1.7	43
20	Cost comparison of two implantable cardiac monitors in two different settings: Reveal XT in a catheterization laboratory vs. Reveal LINQ in a procedure room. <i>Europace</i> , 2016, 18, 919-924.	0.7	22
21	A conceptual disease model for adult Pompe disease. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 112.	1.2	10
22	Quality of Life and Participation in the Daily Life (Activities) of Adults with Pompe Disease Receiving Enzyme Replacement Therapy: 10 Years of International Follow-Up. <i>Journal of Neuromuscular Diseases</i> , 2015, 2, S63-S63.	1.1	1
23	Access to orphan drugs in western Europe: can more systematic policymaking really help to avoid different decisions about the same drug?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 557-559.	0.7	13
24	Orphan drugs expenditure in the Netherlands in the period 2006-2012. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 154.	1.2	23
25	Multi-Criteria Decision Analysis for Reimbursing Orphan Drugs: A Dutch Demonstration Study Using the Analytic Hierarchy Process Method. <i>Value in Health</i> , 2014, 17, A541-A542.	0.1	6
26	Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 75.	1.2	26
27	Systematic review of available evidence on 11 high-priced inpatient orphan drugs. <i>Orphanet Journal of Rare Diseases</i> , 2013, 8, 124.	1.2	19
28	The impact of informal care for patients with Pompe disease: An application of the CarerQol instrument. <i>Molecular Genetics and Metabolism</i> , 2013, 110, 281-286.	0.5	18
29	A new prevention paradox: The trade-off between reducing incentives for risk selection and increasing the incentives for prevention for health insurers. <i>Social Science and Medicine</i> , 2013, 76, 150-158.	1.8	3
30	Burden of illness of Pompe disease in patients only receiving supportive care. <i>Journal of Inherited Metabolic Disease</i> , 2011, 34, 1045-1052.	1.7	29